

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.usplo.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/747,029	12/21/2000	Ann Union	11362.0031.NPUS00	3297
7590 08/24/2004			EXAMINER	
Patricia A. Kammerer Howrey Simon Arnold & White, LLP 750 Bering Drive Houston, TX 77057-2198			DIBRINO, MARIANNE NMN	
			ART UNIT	PAPER NUMBER
			1644	
			DATE MAILED: 08/24/2004	

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)				
Advisory Action	09/747,029	UNION ET AL2				
rancery rioden	Examiner	Art Unit				
	DiBrino Marianne	1644				
The MAILING DATE of this communication appears on the cover sheet with the correspondence address						
THE REPLY FILED 03 May 2004 FAILS TO PLACE THIS Therefore, further action by the applicant is required to averal rejection under 37 CFR 1.113 may only be either: (1) condition for allowance; (2) a timely filed Notice of Appeal Examination (RCE) in compliance with 37 CFR 1.114.	oid abandonment of this applica a timely filed amendment which	tion. A proper reply to a				
PERIOD FOR RE	PLY [check either a) or b)]					
a) The period for reply expiresmonths from the mailing b) The period for reply expires on: (1) the mailing date of this A no event, however, will the statutory period for reply expire to ONLY CHECK THIS BOX WHEN THE FIRST REPLY WAS 706.07(f). Extensions of time may be obtained under 37 CFR 1.136(a). The dee have been filed is the date for purposes of determining the period of fee under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the condition of the co	dvisory Action, or (2) the date set forth a ter than SIX MONTHS from the mailing FILED WITHIN TWO MONTHS OF TH date on which the petition under 37 CFF extension and the corresponding amoune he shortened statutory period for reply of elater than three months after the mailing	date of the final rejection. E FINAL REJECTION. See MPEP R 1.136(a) and the appropriate extension and the fee. The appropriate extension wighly set in the final Office action: or				
 1. A Notice of Appeal was filed on Appellant's Brief must be filed within the period set forth in 37 CFR 1.192(a), or any extension thereof (37 CFR 1.191(d)), to avoid dismissal of the appeal. 2. The proposed amendment(s) will not be entered because: 						
 (a) \infty they raise new issues that would require further consideration and/or search (see NOTE below); (b) \infty they raise the issue of new matter (see Note below); 						
(c) Methey are not deemed to place the application in better form for appeal by materially reducing or simplifying the issues for appeal; and/or						
(d) ☐ they present additional claims without canceling a corresponding number of finally rejected claims.NOTE:						
Applicant's reply has overcome the following rejection	on(s):					
4. Newly proposed or amended claim(s) would be allowable if submitted in a separate, timely filed amendment canceling the non-allowable claim(s).						
5. The a) affidavit, b) exhibit, or c) request for reconsideration has been considered but does NOT place the application in condition for allowance because:						
The affidavit or exhibit will NOT be considered because it is not directed SOLELY to issues which were newly raised by the Examiner in the final rejection.						
7. ☑ For purposes of Appeal, the proposed amendment(s) a) ☑ will not be entered or b) ☐ will be entered and an explanation of how the new or amended claims would be rejected is provided below or appended.						
The status of the claim(s) is (or will be) as follows:						
Claim(s) allowed:						
Claim(s) objected to:						
Claim(s) rejected: 1-4,8,9,12-14,18,20,23,28 and 29. Claim(s) withdrawn from consideration:						
B. \square The drawing correction filed on $___$ is a) \square approved or b) \square disapproved by the Examiner.						
P.☐ Note the attached Information Disclosure Statement(s)(PTO-1449) Paper No(s)						
0.⊠ Other: <u>See Continuation Sheet</u>						
Mariane D						

Continuation of 10. Other: The inclusion of "or antibody specific for at least one peptide of claim 1" in the proposed amendment to claim 12, and the proposed deletion of "diagnostic" from claim 13 raise new issues that would require further consideration and/or search.

CHRISTINA CHAN
SUPERVISORY PATENT EXAMINER

TECHNOLOGY CENTER 1600